miR‑133b is a potential diagnostic biomarker for Alzheimer's disease and has a neuroprotective role

Yang, Qin; Zhao, Qiuling; Yin, Yanliang

doi:10.3892/etm.2019.7855

Cited by 32 publications

(26 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 5 , 6 Wang et al 7 reported that the expression levels of miR-433 were reduced in AD patients and that this miRNA has the potential to be a therapeutic target through improving Aβ-induced neurotoxicity. Yang et al 8 provided evidence for miR-133b to serve as a diagnostic biomarker of AD and revealed its neuroprotective role, which is exerted through maintenance of neuronal viability. Although increasing numbers of miRNAs have been discovered, their practical applications in the diagnosis of AD are still limited.…”

Section: Introductionmentioning

confidence: 99%

Serum miR-128 Serves as a Potential Diagnostic Biomarker for Alzheimer’s Disease

Zhang¹,

Han²,

Xu³

et al. 2021

NDT

View full text Add to dashboard Cite

Background Although numerous microRNAs (miRNAs) have been discovered to participate in the progression of Alzheimer’s disease (AD), they are still difficult to apply in clinical work. Thus, the identification of novel miRNAs and clarification of their clinical significance are importing for improving the diagnosis and treatment of AD. The purpose of this study was to analyze the expression of miR-128 and its diagnostic value in patients with AD. Patients and Methods In this study, 117 AD patients and 106 controls were enrolled, and the demographic data, biochemical parameters and serum miR-128 levels were collected. These data were then used to build a logistic regression model, and receiver operating characteristic (ROC) curves were drawn to evaluate the diagnostic value of miR-128. The relationships between miR-128 and inflammatory factors (IL-1β/TNF-α) were also analyzed from clinical serum data. Results Our study found that miR-128 was significantly upregulated in the serum samples of AD patients compared with controls, and that this upregulation was negatively correlated with Mini-Mental State Examination (MMSE) scores ( r = −0.687, P < 0.01). ROC curve showed that the area under the curve of miR-128 was 0.831. Logistic regression analyses showed that glycosylated hemoglobin (HbA1c) levels, low-density lipoprotein (LDL) levels, MMSE scores and serum miR-128 levels were statistically significant ( P < 0.01), and the ROC curve of the combined detection of these variables was 0.906. The serum miR-128 levels in AD patients were positively correlated with the serum IL-1β ( r =0.798, P <0.01) and serum TNF-α levels ( r =0.733, P <0.01). Conclusion Serum miR-128 is a candidate diagnostic biomarker in AD patients who achieved good diagnostic performance when used alone or in combination with other factors and may have the potential to be a novel therapeutic target for neuroinflammation.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum miR-128 Serves as a Potential Diagnostic Biomarker for Alzheimer’s Disease

Zhang¹,

Han²,

Xu³

et al. 2021

NDT

View full text Add to dashboard Cite

show abstract

“…Thus, high levels of miR-133b could contribute to lowering the expression of FAIM in these neurons. However, in Alzheimer’s disease, miR-133b was found to be significantly downregulated after Aβ25-35 treatment ( Yang et al, 2019 ). In a different study, FAIM levels also appear to be reduced in hippocampal samples from AD patients ( Carriba et al, 2015 ), thus suggesting that the miR-133b-FAIM axis would not be relevant in this disease and opens up the question of whether other miRNAs could be responsible for FAIM downregulation.…”

Section: Discussionmentioning

confidence: 99%

FAIM Is Regulated by MiR-206, MiR-1-3p and MiR-133b

Coccia

Masanas

López‐Soriano

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Apoptosis plays an important role during development, control of tissue homeostasis and in pathological contexts. Apoptosis is executed mainly through the intrinsic pathway or the death receptor pathway, i.e., extrinsic pathway. These processes are tightly controlled by positive and negative regulators that dictate pro- or anti-apoptotic death receptor signaling. One of these regulators is the Fas Apoptotic Inhibitory Molecule (FAIM). This death receptor antagonist has two main isoforms, FAIM-S (short) which is the ubiquitously expressed, and a longer isoform, FAIM-L (long), which is mainly expressed in the nervous system. Despite its role as a death receptor antagonist, FAIM also participates in cell death-independent processes such as nerve growth factor-induced neuritogenesis or synaptic transmission. Moreover, FAIM isoforms have been implicated in blocking the formation of protein aggregates under stress conditions or de-regulated in certain pathologies such as Alzheimer’s and Parkinson’s diseases. Despite the role of FAIM in physiological and pathological processes, little is known about the molecular mechanisms involved in the regulation of its expression. Here, we seek to investigate the post-transcriptional regulation of FAIM isoforms by microRNAs (miRNAs). We found that miR-206, miR-1-3p, and miR-133b are direct regulators of FAIM expression. These findings provide new insights into the regulation of FAIM and may provide new opportunities for therapeutic intervention in diseases in which the expression of FAIM is altered.

show abstract

“…Serum miR-133b levels in AD patients are positively correlated with the simple intelligence status test score. The area under the ROC curve of miR-133b in the diagnosis of AD was 0.907, with 1.7 as the critical value, with a sensitivity of 90.8% and a specificity of 74.3% ( Yang et al, 2019 ). There was a significant positive correlation between the serum level of miR-193a-3p and the MMSE score in AD patients ( Cao et al, 2020 ).…”

Section: Mirnas Help With the Diagnosis Of Admentioning

confidence: 99%

MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers

Wei

Wang

et al. 2020

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the most common form of dementia. Although the incidence of AD is high, the rates of diagnosis and treatment are relatively low. Moreover, effective means for the diagnosis and treatment of AD are still lacking. MicroRNAs (miRNAs, miRs) are non-coding RNAs that play regulatory roles by targeting mRNAs. The expression of miRNAs is conserved, temporal, and tissue-specific. Impairment of microRNA function is closely related to AD pathogenesis, including the betaamyloid and tau hallmarks of AD, and there is evidence that the expression of some microRNAs differs significantly between healthy people and AD patients. These properties of miRNAs endow them with potential diagnostic and therapeutic value in the treatment of this debilitating disease. This review provides comprehensive information about the regulatory function of miRNAs in AD, as well as potential applications as diagnostic biomarkers.

show abstract

miR‑133b is a potential diagnostic biomarker for Alzheimer's disease and has a neuroprotective role

Cited by 32 publications

References 50 publications

Serum miR-128 Serves as a Potential Diagnostic Biomarker for Alzheimer’s Disease

Serum miR-128 Serves as a Potential Diagnostic Biomarker for Alzheimer’s Disease

FAIM Is Regulated by MiR-206, MiR-1-3p and MiR-133b

MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers

Contact Info

Product

Resources

About